OPKO Health, Inc. (NASDAQ:OPK) Receives $2.63 Average Target Price from Analysts

OPKO Health, Inc. (NASDAQ:OPK) has received an average recommendation of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $2.6250.

A number of brokerages have issued reports on OPK. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a report on Wednesday, October 8th. Zacks Research raised OPKO Health from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. Finally, LADENBURG THALM/SH SH raised OPKO Health to a “strong-buy” rating in a report on Tuesday, July 8th.

Insider Activity

In related news, CEO Phillip Md Et Al Frost acquired 675,000 shares of the business’s stock in a transaction on Friday, August 8th. The stock was bought at an average cost of $1.32 per share, with a total value of $891,000.00. Following the completion of the acquisition, the chief executive officer owned 214,676,448 shares in the company, valued at $283,372,911.36. The trade was a 0.32% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 49.69% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Sculptor Capital LP acquired a new stake in OPKO Health in the first quarter worth about $21,111,000. Graham Capital Management L.P. raised its position in shares of OPKO Health by 214.7% in the 1st quarter. Graham Capital Management L.P. now owns 1,810,392 shares of the biotechnology company’s stock valued at $3,005,000 after acquiring an additional 3,388,292 shares during the period. Geode Capital Management LLC raised its position in shares of OPKO Health by 23.7% in the 2nd quarter. Geode Capital Management LLC now owns 10,424,473 shares of the biotechnology company’s stock valued at $13,763,000 after acquiring an additional 1,995,633 shares during the period. Millennium Management LLC grew its position in shares of OPKO Health by 39.2% in the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after purchasing an additional 1,798,385 shares during the period. Finally, Nuveen LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at approximately $2,286,000. 64.63% of the stock is owned by institutional investors.

OPKO Health Stock Down 1.3%

Shares of OPK stock opened at $1.50 on Friday. The stock has a market cap of $1.19 billion, a P/E ratio of -6.00 and a beta of 1.50. OPKO Health has a one year low of $1.11 and a one year high of $2.04. The stock has a fifty day moving average price of $1.45 and a 200 day moving average price of $1.38. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). The company had revenue of $156.80 million for the quarter, compared to the consensus estimate of $165.74 million. OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The firm’s revenue was down 13.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.01) earnings per share. Analysts predict that OPKO Health will post -0.25 earnings per share for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.